Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

ONTX was reduced by Zacks.com  from a “buy” score to a “hold” ranking in a research note provided to capitalists on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm. It focuses on finding and establishing tiny molecule drug candidates to deal with cancer cells. The Firm‘s items under various phases of development consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several other equities research experts likewise lately commented on the firm. Noble Financial reissued a “buy” score and released a $11.00 rate objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 as well as established a “acquire” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. The business has a 50 day relocating ordinary rate of $2.90 as well as a two-hundred day relocating typical rate of $4.16. The firm has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly revenues outcomes on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) profits per share for the quarter, topping experts’ agreement price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% and also an unfavorable internet margin of 8,294.27%. The firm had earnings of $0.06 million during the quarter, contrasted to the agreement quote of $0.06 million. During the same quarter in the previous year, the firm uploaded ($ 0.45) EPS. En masse, research experts forecast that Onconova Therapeutics will publish -1.18 EPS for the existing year.

A variety of hedge funds have actually lately dealt shares of ONTX. GSA Funding Allies LLP got a brand-new position in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Funding Management LP acquired a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC purchased a brand-new position in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC bought a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP acquired a new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and also various other institutional capitalists own 13.36% of the business’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which engages in the identification as well as advancement of oncology therapeutics. It concentrates on finding and also developing small particle medicine prospects to treat cancer. The firm was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Obtain a totally free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

For additional information concerning research offerings from Zacks Investment Research, go to Zacks.com.

This instant information alert was created by narrative science technology as well as monetary information from Market in order to offer visitors with the fastest and most precise coverage. This story was examined by Market’s editorial team prior to publication. 

 

SHOULD YOU SPEND $1,000 IN ONCONOVA THERAPEUTICS TODAY?

Prior to you think about Onconova Therapeutics, you’ll want to hear this.

Market monitors Wall Street’s top-rated and also best performing research analysts and the stocks they advise to their customers every day. Market has recognized the five stocks that cover analysts are quietly whispering to their customers to get now before the broader market catches on … as well as Onconova Therapeutics had not been on the list.

While Onconova Therapeutics currently has a “Buy” rating amongst experts, top-rated analysts think these 5 stocks are better purchases.